A biotech reckoning: 'We've lost our luster in cell therapies'
A Special Report from the Fierce Biotech team on the state of cell therapy.
Source: fiercebiotech.com
Sami Corwin News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Sami Corwin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Sami Corwin Today - Breaking & Trending Today
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q1 2024 Earnings Call Transcript
PTC Therapeutics, Inc. beats earnings expectations. Reported EPS is $-1.2, expectations were $-1.31. PTC Therapeutics, Inc.
Source: insidermonkey.com
Bluebird Bio gets gene therapy approval but no business boost
The company’s stock fell by more than 40 percent Friday after the approval of Lyfgenia, the release of its pricing, and comparison to a less expensive gene-edited drug approved the same day.
Source: bostonglobe.com
FDA Approves Not One, But Two Sickle Cell Disease Gene Therapies
The first gene therapies for sickle cell disease are now approved: Casgevy from Vertex Pharmaceuticals Casgevy and Lyfgenia from Bluebird Bio. Despite the same-day approval, key differences give one of these therapies commercialization advantages over the other.
Source: medcitynews.com
Novartis to Pay Legend Biotech $100M in Pact Bringing Cell Therapy to Solid Tumors
Novartis gains global rights to Legend Biotech cell therapies that address DLL3, a promising target for lung cancers and other types of solid tumors. The pharmaceutical giant may make these therapies using T-Charge, its next-generation CAR T-cell therapy manufacturing technology.
Source: medcitynews.com